Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024015493
Abstract: Key Points • Only 40% of intolerance AEs in cohort 1 (ibrutinib intolerance) and 28% in cohort 2 (acalabrutinib intolerance) recurred with zanubrutinib.• After switching to zanubrutinib, 71% of patients in cohort 1 and 63%… read more here.
Keywords: tolerated effective; ibrutinib; effective patients; patients cll ... See more keywords
Graves’ hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up
Sign Up to like & getrecommendations! Published in 2024 at "European Thyroid Journal"
DOI: 10.1530/etj-24-0085
Abstract: Objective As thionamide is associated with various adverse effects, we re-evaluated the practical efficacy of potassium iodide (KI) therapy for Graves’ hyperthyroidism (GD). Methods We administered KI (mainly 100 mg/day) to 324 untreated GD patients… read more here.
Keywords: patients weeks; effective patients; therapy; potassium iodide ... See more keywords